Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw a 26.05% drop in its stock price after the FDA rejected its biologics license application for the UX111 (ABO-102) treatment for Sanfilippo syndrome. The FDA requested additional information regarding certain manufacturing aspects, but Ultragenyx plans to resubmit the data. The company’s new treatment aims to manage symptoms as there are currently no approved disease-modifying medicines for this genetic condition. Investors are advised to consider other AI stocks for potential higher returns.

Read more at Yahoo Finance: Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light